Evidence map›Paper›PMID 31475931›Full record

Observational studyJournal of musculoskeletal & neuronal interactions2019

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.

Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, Martina Rauner, Linda Sonnleitner, Gerhard Hawa, Elena Tsourdi, Maria P Yavropoulou, Albert Missbichler, Evangelos Terpos

Open access · greenAbstract readObservational Study
PubMed Full text at PMC
In one paragraph

Observational study in Journal of musculoskeletal & neuronal interactions, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Athanasios D AnastasilakisDepartment of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
Stergios A PolyzosFirst Department of Pharmacology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Polyzois MakrasDepartment of Medical Research and Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, Greece.
Martina RaunerDepartment of Medicine III.
Linda SonnleitnerFIANOSTICS GmbH, Wiener Neustadt, Austria.
Gerhard HawaFIANOSTICS GmbH, Wiener Neustadt, Austria.
Elena TsourdiDepartment of Medicine III.
Maria P Yavropoulou1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Albert MissbichlerFIANOSTICS GmbH, Wiener Neustadt, Austria.
Evangelos TerposDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
National and Kapodistrian University of Athens · GRTechnische Universität Dresden · DE424 General Military Hospital · GRAristotle University of Thessaloniki · GRHellenic Air Force · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesNoggin inactivates bone morphogenetic proteins (BMPs), possibly exerting negative effects on the skeleton.We aimed to compare the effect of agents with opposite impact on bone turnover on noggin circulating levels.

methodsIn this observational, open label, non-randomized clinical study postmenopausal women with low bone mass were treated with either denosumab (n=30) or teriparatide (n=30). Serum samples were obtained at baseline, three and twelve months after treatment initiation. Prevalent fractures were recorded at baseline and lumbar spine bone mineral density (LS BMD) was measured at baseline and twelve months. Measured parameters included noggin, BMP-2, BMP-4, procollagen type 1 N-terminal propeptide (P1NP) and C-terminal cross-linking telopeptide of type 1 collagen (CTx).

resultsNoggin levels remained unchanged after either denosumab or teriparatide treatment. Baseline noggin levels were not different between women with vs. without previous anti-osteoporotic treatment, or between those with vs. without vertebral or non-vertebral fractures and were not correlated with age or LS BMD. At twelve months, noggin levels were positively correlated with P1NP within the denosumab (r

conclusionsIn postmenopausal women with low bone mass noggin levels were not correlated with bone parameters at any time point, except with P1NP at 12 months, and remained stable with both denosumab and teriparatide treatment.

Indexed as

AgedAged, 80 and overBone Density Conservation AgentsCarrier ProteinsDenosumabFemaleHumansMiddle AgedNoggin ProteinOsteoporosis, PostmenopausalTeriparatideBone Density Conservation AgentsCarrier ProteinsDenosumabNoggin ProteinTeriparatideBMPDenosumabNogginOsteoporosisTeriparatide

Identifiers

PMID31475931
PMCPMC6737552
OpenAlexW3010455648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.